Aster Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.92K Buy
+42
New +$5.99K ﹤0.01% 825
2025
Q4
– Sell
-83
Closed -$5.51K – 1357
2025
Q3
$5.51K Buy
+83
New +$4.72K ﹤0.01% 796
2025
Q2
– Sell
-1,617
Closed -$60.8K – 1467
2025
Q1
$60.8K Buy
+1,617
New +$67.8K 0.01% 764

Other funds holding PTGX

Aster Capital Management's PTGX Position: Q3 2026 in Review

Aster Capital Management opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 42 shares worth $5.92K. The stake represents ﹤0.01% of the portfolio and ranks #825 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in PTGX as recently as Q3 2025.

Aster Capital Management first reported a position in PTGX in Q1 2025 and has held it in 3 quarters since. The position peaked at $60.8K in Q1 2025. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Aster Capital Management held 42 shares of Protagonist Therapeutics worth $5.92K as of Q3 2026.
  • Protagonist Therapeutics was a new Aster Capital Management position in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q3 2026, its #825 holding.
  • Aster Capital Management first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Aster Capital Management's Protagonist Therapeutics position peaked at $60.8K in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.